Georgina S Butler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7741975/publications.pdf

Version: 2024-02-01

39	5,412	126907	302126
papers	citations	33 h-index	39 g-index

39	39	39	6008
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. Cell Reports, 2021, 37, 109892.	6.4	60
2	Moonlighting matrix metalloproteinase substrates: Enhancement of proinflammatory functions of extracellular tyrosyl-tRNA synthetase upon cleavage. Journal of Biological Chemistry, 2020, 295, 2186-2202.	3.4	17
3	Matrix metalloproteinases inactivate the proinflammatory functions of secreted moonlighting tryptophanyl-tRNA synthetase. Journal of Biological Chemistry, 2019, 294, 12866-12879.	3.4	20
4	The Role of MMP8 in Cancer: A Systematic Review. International Journal of Molecular Sciences, 2019, 20, 4506.	4.1	69
5	Aging-associated modifications of collagen affect its degradation by matrix metalloproteinases. Matrix Biology, 2018, 65, 30-44.	3.6	109
6	New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2043-2055.	4.1	122
7	Degradomic and yeast 2-hybrid inactive catalytic domain substrate trapping identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). Matrix Biology, 2017, 59, 23-38.	3.6	29
8	Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie, 2016, 122, 110-118.	2.6	42
9	TAILS N-Terminomics and Proteomics Show Protein Degradation Dominates over Proteolytic Processing by Cathepsins in Pancreatic Tumors. Cell Reports, 2016, 16, 1762-1773.	6.4	66
10	Active site specificity profiling datasets of matrix metalloproteinases (MMPs) 1, 2, 3, 7, 8, 9, 12, 13 and 14. Data in Brief, 2016, 7, 299-310.	1.0	21
11	Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biology, 2016, 49, 37-60.	3.6	177
12	Macrophage Matrix Metalloproteinase-12 Dampens Inflammation and Neutrophil Influx in Arthritis. Cell Reports, 2014, 9, 618-632.	6.4	93
13	A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nature Medicine, 2014, 20, 493-502.	30.7	218
14	Matrix metalloproteinase processing of signaling molecules to regulate inflammation. Periodontology 2000, 2013, 63, 123-148.	13.4	42
15	A Statistics-based Platform for Quantitative N-terminome Analysis and Identification of Protease Cleavage Products. Molecular and Cellular Proteomics, 2010, 9, 912-927.	3.8	68
16	Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics. Molecular and Cellular Proteomics, 2010, 9, 894-911.	3.8	240
17	Identification of Cellular MMP Substrates Using Quantitative Proteomics: Isotope-Coded Affinity Tags (ICAT) and Isobaric Tags for Relative and Absolute Quantification (iTRAQ). Methods in Molecular Biology, 2010, 622, 451-470.	0.9	26
18	Matrix metalloproteinase proteomics: substrates, targets, and therapy. Current Opinion in Cell Biology, 2009, 21, 645-653.	5.4	239

#	Article	IF	Citations
19	Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nature Reviews Drug Discovery, 2009, 8, 935-948.	46.4	127
20	Updated Biological Roles for Matrix Metalloproteinases and New â€œIntracellularâ€•Substrates Revealed by Degradomics. Biochemistry, 2009, 48, 10830-10845.	2.5	195
21	Metadegradomics. Molecular and Cellular Proteomics, 2008, 7, 1925-1951.	3.8	134
22	Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding. Molecular and Cellular Biology, 2008, 28, 4896-4914.	2.3	149
23	Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Complexes by MMP-2 Proteolysis. Molecular and Cellular Biology, 2007, 27, 8454-8465.	2.3	200
24	Protease Yoga: Extreme Flexibility of a Matrix Metalloproteinase. Structure, 2007, 15, 1159-1161.	3.3	57
25	Proteolytic processing of SDF-1Â reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19182-19187.	7.1	97
26	Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin Î±vÎ²3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and Î±vÎ²3 Are Critical. Cancer Research, 2005, 65, 9377-9387.	0.9	65
27	Characterization of the Distinct Collagen Binding, Helicase and Cleavage Mechanisms of Matrix Metalloproteinase 2 and 14 (Gelatinase A and MT1-MMP). Journal of Biological Chemistry, 2004, 279, 43336-43344.	3.4	146
28	The Canonical Methionine 392 of Matrix Metalloproteinase 2 (Gelatinase A) Is Not Required for Catalytic Efficiency or Structural Integrity. Journal of Biological Chemistry, 2004, 279, 15615-15620.	3.4	43
29	HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nature Neuroscience, 2003, 6, 1064-1071.	14.8	295
30	Collagen Binding Properties of the Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Hemopexin C Domain. Journal of Biological Chemistry, 2002, 277, 39005-39014.	3.4	123
31	Mannose-binding Lectin (MBL) Mutants Are Susceptible to Matrix Metalloproteinase Proteolysis. Journal of Biological Chemistry, 2002, 277, 17511-17519.	3.4	45
32	Utilization of a Novel Recombinant Myoglobin Fusion Protein Expression System to Characterize the Tissue Inhibitor of Metalloproteinase (TIMP)-4 and TIMP-2 C-terminal Domain and Tails by Mutagenesis. Journal of Biological Chemistry, 2002, 277, 48696-48707.	3.4	31
33	Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1. Journal of Biological Chemistry, 2001, 276, 43503-43508.	3.4	576
34	Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent Pathway. Journal of Biological Chemistry, 2001, 276, 47402-47410.	3.4	156
35	The Specificity of TIMP-2 for Matrix Metalloproteinases Can Be Modified by Single Amino Acid Mutations. Journal of Biological Chemistry, 1999, 274, 20391-20396.	3.4	73
36	Human Tissue Inhibitor of Metalloproteinases 3 Interacts with Both the N- and C-terminal Domains of Gelatinases A and B. Journal of Biological Chemistry, 1999, 274, 10846-10851.	3.4	103

#	Article	IF	Citations
37	The TIMP2 Membrane Type 1 Metalloproteinase â€œReceptorâ€•Regulates the Concentration and Efficient Activation of Progelatinase A. Journal of Biological Chemistry, 1998, 273, 871-880.	3.4	524
38	Membrane-Type-2 Matrix Metalloproteinase Can Initiate the Processing of Progelatinase A and is Regulated by the Tissue Inhibitors of Metalloproteinases. FEBS Journal, 1997, 244, 653-657.	0.2	141
39	The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation. Journal of Biological Chemistry, 1996, 271, 17119-17123.	3.4	474